ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1001

Anti-Fractalkine Monoclonal Antibody Dislodges Intravascular Monocytes Involved in Exacerbation of Synovial Inflammation in Collagen-Induced Arthritis Model

Wataru Ikeda1, Kana Hoshino-Negishi1, Eri Fusaoka-Nishioka1, Tomoya Nakatani1, Yoshikazu Kuboi1, Naoto Ishii1, Nobuyuki Yasuda1 and Toshio Imai2, 1KAN Research Institute, Inc., Kobe, Japan, 2President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cell Migration, Chemokine Receptors, chemokines, imaging techniques and monocytes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Cytokines and Cell Trafficking Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately controlled by MTX and/or TNF-α inhibitors. In preclinical study, anti-FKN mAb significantly lowered arthritis score of CIA model, and reduced infiltration of inflammatory cells and bone erosion in the synovium (Nanki et al., J Immunol 2004). Furthermore, anti-FKN mAb reduced the migration of adoptively transferred splenic monocytes/macrophages into the inflamed synovium. FKN is expressed on endothelial cells and fibroblast-like synoviocytes and also expressed on osteoblasts. CX3CR1, the receptor for FKN, is expressed on monocytes/macrophages and osteoclast precursors. Moreover, intravascular monocytes contribute vascular inflammation. However, the roles of FKN and CX3CR1 in the pathogenesis of RA, especially the behavior of intravascular monocytes, remain unclear. In this study, we evaluated the role of FKN-CX3CR1 axis on intravascular monocyte behavior in synovium of CIA model by intravital imaging and tissue-clearing techniques.

Methods: For the induction of CIA, mice were immunized with bovine type II collagen. The effect of anti-FKN mAb on synovium of MCP joint was examined by intravital imaging and three-dimensional (3D) tissue analysis with tissue-clearing technique. In intravital imaging, we established a system for MCP joint observation by two-photon laser scanning microscope (TPLSM), and the behavior of intravascular monocytes visualized by anti-CD115 mAb were compared in the presence or absence of anti-FKN mAb or control IgG. 3D tissue analysis was performed by tissue-clearing reagent LUCID (WO 2014115206 A1) and TPLSM. One hour after anti-FKN mAb or control IgG administration, the mice underwent to low-speed perfusion fixation so that the cells attached to the blood vessels did not detach. Before fixation, intravascular monocytes and blood vessels were visualized by anti-CD115 mAb and RCA-1, respectively. The number of intravascular monocytes were quantified. In order to clarify the difference of point of action with other biologics, the same experiment was carried out with TNF-α inhibitor or CTLA4-Ig administration.

Results: In intravital imaging, angiogenesis in the synovium of CIA occurred actively, and adhered and/or slow-paced monocytes appeared in the vasculature. At thirty minutes after anti-FKN mAb administration, the intravascular monocytes were reduced, but control IgG did not change compared to before administration. In tissue transparency analysis, the number of intravascular monocytes was markedly reduced by anti-FKN mAb as compared with control IgG. When the same experiments were performed with TNF-α inhibitor or CTLA4-Ig, intravascular monocytes were not reduced.

Conclusion: Intravital imaging and tissue-clearing techniques revealed that anti-FKN mAb dislodges intravascular monocytes in inflamed synovium. These results suggest that the FKN–CX3CR1 axis regulates intravascular monocyte behavior in inflamed synovium, such as enhancement of vascular inflammation and infiltration of osteoclast precursors. FKN–CX3CR1 blockade may be a novel attractive strategy for the treatment of RA.


Disclosure: W. Ikeda, KAN Research Institute, Inc., 3; K. Hoshino-Negishi, KAN Research Institute, Inc., 3; E. Fusaoka-Nishioka, KAN Research Institute, Inc., 3; T. Nakatani, KAN Research Institute, Inc., 3; Y. Kuboi, KAN Research Institute, Inc., 3; N. Ishii, KAN Research Institute, Inc., 3; N. Yasuda, KAN Research Institute, Inc., 3; T. Imai, KAN Research Institute, Inc., 3.

To cite this abstract in AMA style:

Ikeda W, Hoshino-Negishi K, Fusaoka-Nishioka E, Nakatani T, Kuboi Y, Ishii N, Yasuda N, Imai T. Anti-Fractalkine Monoclonal Antibody Dislodges Intravascular Monocytes Involved in Exacerbation of Synovial Inflammation in Collagen-Induced Arthritis Model [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/anti-fractalkine-monoclonal-antibody-dislodges-intravascular-monocytes-involved-in-exacerbation-of-synovial-inflammation-in-collagen-induced-arthritis-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-fractalkine-monoclonal-antibody-dislodges-intravascular-monocytes-involved-in-exacerbation-of-synovial-inflammation-in-collagen-induced-arthritis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology